Advertisement

Table of Contents

August 01, 1996; Volume 50,Issue 2

You have access
Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
I Bouchelet, Z Cohen, B Case, P Séguéla and E Hamel

Molecular Pharmacology August 1996, 50 (2) 219-223;
You have access
Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor.
R A Nicholas, W C Watt, E R Lazarowski, Q Li and K Harden

Molecular Pharmacology August 1996, 50 (2) 224-229;
You have access
Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus.
S R Glaum, M Hara, V P Bindokas, C C Lee, K S Polonsky, G I Bell and R J Miller

Molecular Pharmacology August 1996, 50 (2) 230-235;
You have access
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
T Yazaki, S Ahmad, A Chahlavi, E Zylber-Katz, N M Dean, S D Rabkin, R L Martuza and R I Glazer

Molecular Pharmacology August 1996, 50 (2) 236-242;
You have access
Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic

Molecular Pharmacology August 1996, 50 (2) 243-248;
You have access
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
C P Tseng and A K Verma

Molecular Pharmacology August 1996, 50 (2) 249-257;
You have access
A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.
T E Webb, D Henderson, B F King, S Wang, J Simon, A N Bateson, G Burnstock and E A Barnard

Molecular Pharmacology August 1996, 50 (2) 258-265;
You have access
Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
H E Melikian, S Ramamoorthy, C G Tate and R D Blakely

Molecular Pharmacology August 1996, 50 (2) 266-276;
You have access
Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants.
D L Duval, D R Miller, J Collier and R E Billings

Molecular Pharmacology August 1996, 50 (2) 277-284;
You have access
Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
M Sautel, K Rudolf, H Wittneben, H Herzog, R Martinez, M Munoz, W Eberlein, W Engel, P Walker and A G Beck-Sickinger

Molecular Pharmacology August 1996, 50 (2) 285-292;
You have access
Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.
K M Standifer, G C Rossi and G W Pasternak

Molecular Pharmacology August 1996, 50 (2) 293-298;
You have access
Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.
E M Sutkowski, J D Robbins, W J Tang and K B Seamon

Molecular Pharmacology August 1996, 50 (2) 299-305;
You have access
Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.
S A Berry, M C Shah, N Khan and B L Roth

Molecular Pharmacology August 1996, 50 (2) 306-313;
You have access
A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
J M Coulson, D R Poyner, A Chantry, W J Irwin and S Akhtar

Molecular Pharmacology August 1996, 50 (2) 314-325;
You have access
Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
S Lecoeur, C André and P H Beaune

Molecular Pharmacology August 1996, 50 (2) 326-333;
You have access
Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation.
Y J Jeon, K H Yang, J T Pulaski and N E Kaminski

Molecular Pharmacology August 1996, 50 (2) 334-341;
You have access
Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene.
E Hedlund, A Wyss, T Kainu, M Backlund, C Köhler, M Pelto-Huikko, J A Gustafsson and M Warner

Molecular Pharmacology August 1996, 50 (2) 342-350;
You have access
Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
S M Wade, M K Scribner, H M Dalman, J M Taylor and R R Neubig

Molecular Pharmacology August 1996, 50 (2) 351-358;
You have access
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
C F Perno, E Balestra, S Aquaro, S Panti, A Cenci, G Lazzarino, B Tavazzi, D Di Pierro, J Balzarini and R Calio

Molecular Pharmacology August 1996, 50 (2) 359-366;
You have access
Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside.
F J Azula, E S Alzola, M Conde, M Trueba, J M Macarulla and A Marino

Molecular Pharmacology August 1996, 50 (2) 367-379;
You have access
Mapping the block of a cloned human inward rectifier potassium channel by dofetilide.
J Kiehn, B Wible, A E Lacerda and A M Brown

Molecular Pharmacology August 1996, 50 (2) 380-387;
You have access
Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
S Y Yao, C E Cass and J D Young

Molecular Pharmacology August 1996, 50 (2) 388-393;
You have access
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq and A Karlsson

Molecular Pharmacology August 1996, 50 (2) 394-401;
You have access
A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors.
M P Mascia, S J Mihic, C F Valenzuela, P R Schofield and R A Harris

Molecular Pharmacology August 1996, 50 (2) 402-406;
You have access
Alpha 2-adrenergic receptors activate phospholipase C in renal epithelial cells.
F A Gesek

Molecular Pharmacology August 1996, 50 (2) 407-414;
You have access
Inhibition of receptor/G protein coupling by suramin analogues.
W Beindl, T Mitterauer, M Hohenegger, A P Ijzerman, C Nanoff and M Freissmuth

Molecular Pharmacology August 1996, 50 (2) 415-423;
You have access
Receptor internalization delays m4 muscarinic acetylcholine receptor resensitization at the plasma membrane.
G S Bogatkewitsch, W Lenz, K H Jakobs and C J Van Koppen

Molecular Pharmacology August 1996, 50 (2) 424-429;
You have access
Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line.
L J Olson, D G Lowe and J G Drewett

Molecular Pharmacology August 1996, 50 (2) 430-435;
You have access
Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
F Schmitz, D S Pratt, M J Wu, L F Kolakowski, M Beinborn and A S Kopin

Molecular Pharmacology August 1996, 50 (2) 436-441;